APC alterations in papillary thyroid carcinoma: molecular mechanisms, clinical implications, and future perspective
Journal of Diabetes & Metabolic Disorders · 21.07.2026 · 25 (2)
DOI: 10.1007/s40200-026-02016-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Diabetes & Metabolic Disorders, online erschienen am 21.07.2026. Verfasst von Azin Soltani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences,…. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer which is characterized by a complex of molecular panels involving genetic and signaling pathway alterations. The major molecular driver of PTC is MAPK signaling pathway, including BRAF, RAS, and RET/PTC, but new evidence suggests the role of Wnt/β-catenin signaling pathway dysregulation in thyroid tumor development and tumor progression. The adenomatous polyposis coli (APC) gene as an important tumor suppressor gene that negatively regulates β-catenin, has attracted attention due to its role in familial adenomatous polyposis (FAP)-associated thyroid carcinoma. This review summarizes the structure and biological function of APC gene, its role in Wnt/β-catenin signaling pathway, and its contribution to the molecular pathogenesis of PTC. Furthermore, the contribution of germline and somatic APC alterations to FAP-associated thyroid tumors, and the molecular mechanisms linking APC dysregulation to thyroid carcinogenesis are discussed. In addition, we reviewed the potential diagnostic, prognostic, and therapeutic implications of APC-related molecular alterations, including their relevance to molecular testing, precision medicine, genetic counseling, and surveillance strategies. Despite the uncommon prevalence of APC mutations in sporadic PTC, some studies suggest the role of APC-related molecular abnormalities in tumor progression and the emergence of aggressive clinicopathological disease subtypes. In addition, APC mutations may have significant clinical value when integrated with other molecular markers of thyroid carcinogenesis. However, the definite clinical significance of APC mutations in PTC emergence is not fully understood, and additional prospective and translational studies are required to elucidate their biological and clinical advantages in diagnosis, prognosis, targeted therapy, and individualized patient management.
Autor:innen und Institutionen
- Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Pathology, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Soltani, A., Razi, F., & Abdollahi, A. (2026). APC alterations in papillary thyroid carcinoma: molecular mechanisms, clinical implications, and future perspective. Journal of Diabetes & Metabolic Disorders, 25(2). https://doi.org/10.1007/s40200-026-02016-0
Vancouver
Soltani A, Razi F, Abdollahi A. APC alterations in papillary thyroid carcinoma: molecular mechanisms, clinical implications, and future perspective. Journal of Diabetes & Metabolic Disorders. 2026;25(2). doi:10.1007/s40200-026-02016-0
BibTeX
@article{Soltani2026,
author = {Soltani, Azin and Razi, Farideh and Abdollahi, Alireza},
title = {APC alterations in papillary thyroid carcinoma: molecular mechanisms, clinical implications, and future perspective},
journal = {Journal of Diabetes & Metabolic Disorders},
year = {2026},
volume = {25},
number = {2},
doi = {10.1007/s40200-026-02016-0}
}
EUVIMED